Merus’ Phase 2 overall survival data reach ‘home run’ scenario — analyst

Max Gelman

Senior Editor

Merus completed its rollout of Phase 2 head and neck cancer data on Thursday, touting overall survival results that at least one analyst said amount …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Merus’ Phase 2 overall survival data reach ‘home run’ scenario — analyst

Max Gelman

Senior Editor

Sign up to read this article for free.

The ‘MAHA report’: Four key takeaways on vaccines, medicine and the pharma industry

Meet the ‘first sale’ rule: A customs loophole pharma companies could use to ease tariff impact

House passes Trump tax bill with PBM and orphan drug reforms included

FDA chief to senators: 3,000+ staff departures won't delay user fee targets

FDA adcomm votes unanimously against Pfizer's prostate cancer drug combo

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Merus’ Phase 2 over­all sur­vival da­ta reach ‘home run’ sce­nario — an­a­lyst

Max Gelman

Senior Editor

Sign up to read this article for free.

The ‘MA­HA re­port’: Four key take­aways on vac­cines, med­i­cine and the phar­ma in­dus­try

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

House pass­es Trump tax bill with PBM and or­phan drug re­forms in­clud­ed

FDA chief to sen­a­tors: 3,000+ staff de­par­tures won't de­lay user fee tar­gets

FDA ad­comm votes unan­i­mous­ly against Pfiz­er's prostate can­cer drug com­bo

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

Merus’ Phase 2 overall survival data reach ‘home run’ scenario — analyst

The ‘MAHA report’: Four key takeaways on vaccines, medicine and the pharma industry

Meet the ‘first sale’ rule: A customs loophole pharma companies could use to ease tariff impact

House passes Trump tax bill with PBM and orphan drug reforms included

FDA chief to senators: 3,000+ staff departures won't delay user fee targets

FDA adcomm votes unanimously against Pfizer's prostate cancer drug combo

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?